echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > One after another, Hengrui's new ADC drug has been approved for clinical use for the first time

    One after another, Hengrui's new ADC drug has been approved for clinical use for the first time

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On October 25, CDE official website showed that Hengrui Medicine's SHR-A1921 clinical trial application was approved by the China Food and Drug Administration


    SHR-A1921 is an antibody-conjugated drug (ADC) for the treatment of advanced malignant solid tumors


    In recent years, Hengrui has also continued to deploy ADC drugs


    Among the 7 Hengrui drugs that entered the clinic, 3 drugs were approved for the first time in 2021, namely SHR-A1912, SHR-A2009, and SHR-A1921


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.